Acceleron Pharma Announces Oral Plenary Presentation For ACE-083 In The Late Breaking Clinical Trials Session At The 8th International Conference On Cachexia, Sarcopenia And Muscle Wasting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, announced that a late breaking abstract describing results from the ACE-083 Phase 1 clinical trial has been selected for an oral plenary presentation in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia, and Muscle Wasting. The conference will take place in Paris, France, December 4-6, 2015.